Coming Off Mounjaro: What to Expect When Stopping Tirzepatide
A week-by-week guide to stopping Mounjaro. What happens when tirzepatide clears your system, why weight regain is common, and what a proper off-ramp plan looks like.
Read article →
Coming Off Wegovy and Ozempic: What to Expect When You Stop Semaglutide
The evidence-backed guide to stopping semaglutide. What happens to appetite, weight, and cardiometabolic markers after you stop, and how to plan the off-ramp properly.
Read article →
SSRI Withdrawal vs Relapse: How to Tell the Difference
A research-heavy guide to distinguishing SSRI withdrawal from depressive relapse. What the evidence says, where the mainstream story falls short, and a more useful clinical framework.
Read article →
Why GLP-1 Drugs Work Better for Some People Than Others
A contrarian look at why GLP-1 drugs work differently, what the new genetics paper actually shows, and what patients should do with that information.
Read article →
SURMOUNT-1 Trial Summary: What Tirzepatide Actually Showed
A plain-English summary of SURMOUNT-1: how effective tirzepatide was in obesity, who the study applied to, and what it still did not answer.
Read article →
STEP 1 Trial Summary: What Semaglutide Actually Showed
A plain-English summary of STEP 1: how much weight semaglutide produced, who the trial applied to, and what it did not prove.
Read article →
What Happens When Tirzepatide Is Stopped? What SURMOUNT-4 Showed
A clear summary of SURMOUNT-4: what happened when tirzepatide was continued, what happened when it was withdrawn, and why that matters for maintenance.
Read article →
What Happens When Semaglutide Is Stopped? What STEP 4 Showed
A clear, evidence-led summary of STEP 4: what happened when semaglutide was continued, what happened when it was stopped, and why that matters clinically.
Read article →
Foundayo: What Lilly's New Weight Loss Pill Really Means
Foundayo is Lilly's new oral GLP-1 pill for weight loss. Here is what it does, how it compares, side effects, and why convenience is not the whole story.
Read article →
Retatrutide Phase 3 Diabetes Results: What They Actually Show
Retatrutide's phase 3 diabetes data look strong on A1C and weight loss. Here is what the trial showed, what most coverage misses, and what patients should do now.
Read article →SURMOUNT-5 Trial Summary: Tirzepatide vs Semaglutide
A clear summary of SURMOUNT-5, the head-to-head obesity trial comparing tirzepatide with semaglutide, and what the result really means in practice.
Read article →SELECT Trial Summary: Semaglutide and Cardiovascular Risk
A clear summary of SELECT, the landmark trial that moved obesity pharmacotherapy from a weight discussion into an outcomes discussion.
Read article →FLOW Trial Summary: Semaglutide and Chronic Kidney Disease
A clear summary of FLOW, which moved semaglutide into the kidney outcomes conversation and showed hard renal benefits in type 2 diabetes with CKD.
Read article →ESSENCE Trial Summary: Semaglutide and MASH
A clear summary of ESSENCE, the phase 3 trial that gave semaglutide histologic evidence in metabolic dysfunction-associated steatohepatitis with fibrosis.
Read article →STEP-HFpEF Trial Summary: Semaglutide for Obesity-Related HFpEF
STEP-HFpEF brought obesity medicine into a syndrome that has long frustrated both patients and cardiologists. Here is what it showed and what it means.
Read article →SUMMIT Trial Summary: Tirzepatide for HFpEF and Obesity
SUMMIT pushed the obesity-HFpEF story beyond symptom relief toward clinical events. Here is what it showed and how it differs from STEP-HFpEF.
Read article →OASIS 1 Trial Summary: Oral Semaglutide for Obesity
OASIS 1 took oral semaglutide for obesity from novelty to plausibility. Here is what the trial showed and what route of administration actually changes.
Read article →